Gene Xpert MTB/RIF Assay – An Effortless Tool for the Rapid Detection of Pulmonary and Extra-Pulmonary Tuberculosis with Detection of Rifampicin (RIF) Resistance

Dr. Sanjeev Kumar[1*], Mr. Rambabu Sharma[2], Dr. SadhanaShanker[3]
[1]Assistant Professor, Department of Microbiology, Pacific Institute of Medical Sciences, Udaipur, Rajasthan, India
[2,3]Tutors, Department of Microbiology, Pacific Institute of Medical Sciences, Udaipur, Rajasthan, India

Abstract: Tuberculosis (TB) is one of the major concerns of health policy and rapid detection of *M. tuberculosis* and detection of rifampicin (RIF) resistance in infected patients are essential for disease management. Multi-drug resistance (MDR) TB is defined as tuberculosis (TB) disease caused by a strain of *Mycobacterium tuberculosis* (MTB) that was resistant to at least isoniazid and rifampicin (RIF). The aim of this study was to evaluate the importance of GeneXpert MTB/RIF for detection of *Mycobacterium tuberculosis* (MTB) with detection of rifampicin (RIF) resistance. In this study 320suspected cases of pulmonary and extra-pulmonary TB were included. Their sputum and other (Pus, CSF, tissue, etc.,) samples were collected and subjected to smear microscopy test followed by GeneXpert MTB/RIF assay. Of total 320 suspected cases, Mycobacteria were detected in 152 patients (47.5%) by GeneXpert MTB/RIF and ZN stain. Among all, the highest detection rate of MTB was found by Genexpert 148(46.2%) followed by ZN smear 114(35.6%). Four ZN smear positive cases were negative by Genexpert MTB/RIF. However, RIF's resistance was detected in only 08 cases (5.4%) by GeneXpert MTB/RIF. GeneXpert MTB/RIF assay is efficient and reliable technique for the rapid diagnostic of TB. The GeneXpert MTB/RIF assay is a simple, high sensitivity and specificity for RIF resistance detection implies for diagnosis of MTB and RIF resistance in MDR cases as well as suspected smear negative and extra-pulmonary cases.
Keywords: *Mycobacterium tuberculosis* (MTB), rifampicin (RIF) resistance, GeneXpert MTB/RIF, ZN stain.

INTRODUCTION

Tuberculosis (TB) is the most common infectious disease worldwide caused by Mycobacterium tuberculosis (MTB) has elicit the need for rapid diagnostic techniques [1]. According to WHO the first milestones of the End TB Strategy, set for 2020, are a 35% reduction in the absolute number of TB deaths and a 20% reduction in the TB incidence rate, compared with levels in 2015. WHO worldwide report in 2015, there were an estimated 10.4 million incident TB cases. An estimated 62% of these cases were male, and 90% of cases were adults and 10% children. Six countries accounted for 60% of the global total: India, Indonesia, China, Nigeria, Pakistan and South Africa. The rate of progress in these countries will have a major influence on whether or not the 2020 global milestones are achieved.

The best estimate is that there were 1.4 million TB deaths in 2015, and an additional 0.4 million deaths resulting from TB disease among HIV-positive people [2]. In terms of cases, the best estimates for 2015 are that there were 10.4 million new TB cases (including 1.2 million among HIV-positive people), of which 5.9 million were among men, 3.5 million among women and 1.0 million among children. Overall, 90% of cases were adults and 10% children.

The only WHO-recommended rapid diagnostic test for detection of TB and rifampicin resistance currently available is the Xpert MTB/RIF® assay. The Xpert® MTB/RIF assay (Cepheid Inc., CA, USA) marks an important development in the field of rapid molecular TB diagnostics [3,4]. This multifunctional diagnostic platform is an automated, closed system that performs real-time PCR and can be used by operators with minimal technical expertise, enabling diagnosis of TB and simultaneous assessment of rifampicin resistance to be completed within 2 h. Sputum samples can be analyzed with very minimal processing, yielding positive diagnoses in 99–100% of patients with smear-positive pulmonary TB and 57–83% of patients with

smear-negative pulmonary TB in clinical evaluation studies.[3]The only rapid test (Xpert® MTB/RIF assay) was initially recommended (in 2010) for diagnosis of pulmonary TB in adults. In October 2013, the WHO released a policy update on GeneXpert (MTB/RIF) which expands the recommended use of GeneXpert(MTB/RIF) as the initial diagnostic test in all individuals (smear negative, paediatric, MDR-TB and HIV) suspected of having pulmonary and extra-pulmonary tuberculosis (EPTB)[5,6].

MATERIALS AND METHODS
Clinical samples
In this study, pulmonary and extra-pulmonary samples obtained from different clinical departments were included. Confirmed sputum smear positive cases also included in this study for detecting the drug resistance.

Processing of samples
AFB smears
Before processing of specimens by Xpert MTB/RIF assay, smears were prepared and stained by the Ziehl-Neelsen (ZN) method and examined with a light microscope for the presence of AFB.

Xpert MTB/RIF assay
Sputum: Sputum samples were processed directly from Xpert MTB/RIF test, according to manufacturer's protocol. Briefly, 2.0ml of GeneXpert MTB/RIF sample reagent was added to 1.0ml of sputum/other specimen in a sterile container using a sterile pipette and the container was manually agitated twice during a 20 minute incubation period at room temperature. Then 2 ml of the inactivated material was transferred to the test cartridge by a sterile disposable pipette (provided with kits). Cartridges were loaded into the GeneXpert. The interpretation of data from MTB/RIF tests was software based and not user dependent [7].

Other than sputum samples
Other than sputum samples were concentrated by cytocentrifugation at 3000g for 20 minutes and the deposit was processed as for sputum sample using, ZN staining, Xpert MTB/RIF assay.

RESULTS
Of the 320 specimens, 152(47.5%) were positive for Mycobacteria by Genexpert MTB/RIF and ZN smear. Among 152 positive cases, 146(96%) were pulmonary, 06(4%) were extra-pulmonary (EP). Among 152 positive patients, 121(79.6%) were males and 31(20.4%) were females. Out of 121 males, 05 were children, 116 were adults and among 31 females, 3 were children, 28 were adults. Among all, the highest detection rate of MTB was found by Genexpert 148(46.2%) followed by ZN smear 114(35.6%). Four ZN smear positive cases were negative by GenexpertMTB/RIF. Of the 148 Genexpert positive samples for MTB, 08(5.4%) cases showed RIF resistance and diagnosed as MDR-TB.

Table-1: Detection of Mycobacterium tuberculosis by GeneXpert comparing with AFB smear examination

	Male		Female		Total (*n=320)	
	Children (0-18Yrs)	Adults (≥19Yrs)	Children (0-18Yrs)	Adults (≥19Yrs)		
[#]AFB Smear +Ve	03	88	02	21	114	320
AFB Smear –Ve	09	145	03	49	206	
GeneXpert[$]Mtb detected	05	112	03	28	148	320
GeneXpertMtb Not-detected	07	121	02	42	172	

#AFB – Acid fast bacilli, $Mtb – Mycobacterium tuberculosis, *n – Number of samples.

DISCUSSION
The increasing incidence of MDR-TB in India and other developing countries is a serious threat to tuberculosis control. The major problem in treatment of TB is delayed diagnosis without drug sensitivity which often leads to MDR-TB. World-wide prevalence of MDR-TB is markedly increasing which demands for the accurate and rapid method for the diagnosis. This will help clinicians in effective treatment, management and control of TB. Therefore the present study was designed to evaluate the importance of the new PCR-based technology (Genexpert MTB/RIF) for the detection of MTB and RIF resistance.

According to the World Health Organization (WHO) 650,000 people are infected worldwide and 12 million suffer from TB. In Africa, 1.9% of new cases and 9.4% of diagnosed and treated patients are infected by MDR strain [8]. The results of this study (5.4%) showed that eight strains harboring mutations in rpoB were phenotypically MDR-TB strains (resistant to RIF). This was very less comparable to 77.4% reported by Olusoji *et al.* [9]. Few studies had documented the presence of cases infected by MDR strains in Nigeria, with prevalent rates ranging from 4–76.3% [10,11], but was much superior to the results found by Rasaki *et al.* [12] where forty four (31.4%) were positive and to another rates published in previous studies from India [13,14].

There was male preponderance, 121 (79.6%) as against 31 (20.4%) female; this was in concord with the work of Ganguly *et al.* [15] where male subjects had prevalence of 85.71% as against 14.29% of females.

Similarly, a European study by Faustini *et al.* [16] observed more TB cases among men. In a another study done by Robert *et al.* [18] the age and the sex distribution was similar to the study of Ganguly et al.[15]This disparity could be due to the fact that male subjects were more exposed to risk factors of TB infection. In the present study, the distribution according to age showed that the majority of patients with TB cases belonged to age group of ≥19 years followed by ≤18 years. This was in concord with the study of Thomas et al. [17].

In the current study the efficacy of the Genexpert (MTB/RIF) for the diagnosis of TB was 148(46.2%) from 320 clinical suspected cases of TB. In the present study Genexpertfor MTB Genexpert showed 100% sensitivity and superior than ZN smear for detecting MTB. Four smear +ve cases showed negative by Genexpert. This is may be due to Mycobacterium other than tuberculosis (MOTT). Different studies about the performance of GeneXpert (MTB/ RIF) have showed the test sensitivities in the range of 57%to 76.9% in cases of culture +ve/smear –ve cases, while 98% to 100% sensitivities were observed in culture +ve/smear +ve cases. The overall specificity of GeneXpert remained at 99% to 100% [19-23].

Our finding that the Z-N smear is less sensitive than the GeneXpert MTB/RIF test is reasonable because the Z-N smear method requires $5x10^3$ to $1x10^4$ bacilli/ml of specimen to generate a positive result. However, the GeneXpert assay only requires 131 bacilli/ml [24, 25].

Additionally, the GeneXpert MTB/RIF assay detects DNA of *Mycobacterium tuberculosis* (MTB). In this study, four isolates were detected by ZN stain, but were negative with the Gene Xpert TB/RIF assay. This is because GeneXpert TB/RIF is a nucleic acid amplification test for detection of distinctive DNA of the MTB complex, exclusive of MOTT [7].

Multidrug-resistant tuberculosis (MDR-TB) is defined as TB caused by strains of M. tuberculosis that are resistant to at least isoniazid and RIF [26]. Mono-resistance to RIF is rare; however, 90% of RIF resistant isolates also exhibit resistance to isoniazid. Therefore, the detection of RIF resistance may serve as a surrogate marker for MDR M. tuberculosis [27]. For RIF resistance detection, Xpert® MTB/RIF provides accurate results and can allow rapid initiation of MDR-TB treatment [28]. In our study, 08 (5.4%) were RIF resistant, while 140 (94.6%) were RIF sensitive. Our study similar to the study of Olusoji et al. [9], Lawson et al. [29], Ganguly et al. [15], where (7.2%), (8.6%), (19%), isolates were resistance to RIF respectively and Idigbe et al. [30] who reported only 2% of resistance to RIF in Lagos, Nigeria. However, no strain of RIF resistant was reported in the findings of Rasakiet al.

[12]. In study conducted by Kheira et al. [31]. Trivedi [13] and Shah [32] reported 21 (42%) were RIF resistant, while 29 (58%) were RIF sensitive respectively. but lower to the study of Chowgule who reported a very high incidence of RIF resistance of (66.8%)[33].

CONCLUSIONS

The Gene Xpert MTB/RIF assay is a simple, rapid, and accurate test method for detecting M.tb in sputum specimens, is less dependent on the operator's skills, and staff with minimal training can use the equipment. Although the Gene Xpert MTB/RIF assay has these advantages, similar to other tests for M. tb, a negative result cannot exclude the diagnosis of TB, and patients with positive results can also be assessed comprehensively with results of the Z-N smear test, culture, clinical symptoms, and radiographic evidence.

The high sensitivity and specificity of Xpert MTB/RIF for RIF resistance detection support its use as an initial diagnostic test for RIF resistance. Therefore, implementation of molecular approaches for direct diagnosis of MDR TB, as a part of routine analysis in the laboratories of health care institutions, would be of great benefit in adapting treatment regimens, limiting dissemination of MDR TB strains. A highly sensitive, cross-platform, diagnostic screening assay for the detection of *Mtb,* directly from decontaminated sputum was developed without a time-consuming nucleic acid extraction procedure making it more suitable for adaptation to point of care (POC) use and with a turnaround time of around one hour.

REFERENCES

1. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, Safi H. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. Journal of clinical microbiology. 2010 Jan 1;48(1):229-37.
2. World Health Organization. Executive Summary, Global Tuberculosis Report. 2012. Available at: http:// www.who.int/tb/publications/global_report/gtbr12_executivesummary.pdf.
3. Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future microbiology. 2011 Sep;6(9):1067-82.
4. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A. Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine. 2010 Sep 9;363(11):1005-15.
5. Ioannidis P, Papaventsis D, Karabela S, Nikolaou S, Panagi M, Raftopoulou E, Konstantinidou E, Marinou I, Kanavaki S. Cepheid GeneXpert

MTB/RIF Assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with high clinical suspicion of TB and smear negative microscopy. Journal of clinical microbiology. 2011 Jun 15:JCM-00718.

6. WHO. Tuberculosis diagnostics automated DNA test. www.who.int/tb/features_archive/ xpert_factsheet.pdf. (101)

7. Bodmer T and Strohle A. Diagnosing pulmonary Tuberculosis with the Xpert MTB/RIF Test. J Vis Exp. 2012; 62:e3547.

8. WHO. Epidemiological fact sheets on HIV and AIDS, 2008 update: Core data on epidemiology and response Djibouti. WHO globalatlas.

9. Olusoji D, Eitayeb O, Olanrewaju O. Global Advance Research. J Microbiol. 2013;2:022-025.

10. Dosumu EA, Osagie K, Shuaib A, Lawson L. Multidrug resistant tuberculosis at the national hospital, Abuja Nigeria. Afr J Respir Med. 2008;4(1):22-3.

11. Daniel O, Osman E. Prevalence and risk factors associated with drug resistant TB in South West, Nigeria. Asian Pac J Trop Med. 2008;4:148-51.

12. Rasaki SO, AJibola AI, Musa SA, Moradeyo AK, Odeigah LO, Abdullateef SG, Adeoti W, Salamat IL. Rifampicin resistant tuberculosis in a secondary health institution in Nigeria, West Africa. Journal of Infectious Diseases and Therapy. 2014 Apr 26.

13. Trivedi SS, Desai SG. Primary antituberculosis drug resistance and acquired rifampicin resistance in Gujarat, India. Tubercle. 1988;69:37-42.

14. Jain NK, Chopra KK, Prasad G. Initial and acquired isoniazid and rifampicin resistance to Mycobacterium tuberculosis and its implication for treatment. Indian J Tuberc. 1992;39:121-4.

15. Ganguly J, Ray S, Nandi S, Halder S, Kundu S, Mandal A. A study to evaluate pattern of rifampicin resistance in cases of sputum positive pulmonary tuberculosis. Journal of Evolution of Medical and Dental Sciences. 2015 Apr 6;4(28):4762-8.

16. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61:158-63.

17. Thomas A, Ramachandran R, Rehaman F, Jaggarajamma K, Santha T, Selvakumar N, Krishnan N, Sunder Mohan N, Sundaram V, Wares F, Narayanan PR. Management of multi drug resistance tuberculosis in the field: Tuberculosis Research Centre experience. Indian Journal of Tuberculosis. 2007;54(3):117-24.

18. Robert J, Trystram D, Truffot-Pernot C, Jarlier V. Multidrug-resistant tuberculosis: eight years of surveillance in France. European respiratory journal. 2003 Nov 1;22(5):833-7.

19. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, Safi H. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. Journal of clinical microbiology. 2010 Jan 1;48(1):229-37.

20. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A. Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine. 2010 Sep 9;363(11):1005-15.

21. Armand S, Vanhuls P, Delcroix G, Courcol R, Lemaître N. Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J ClinMicrob. 2011; 49: 1772-6.

22. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. The lancet. 2011 Apr 30;377(9776):1495-505.

23. Marlowe EM, Novak-Weekley SM, Cumpio J, Sharp SE, Momeny MA, Babst A, Carlson JS, Kawamura M, Pandori M. Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. Journal of clinical microbiology. 2011 Apr 1;49(4):1621-3.

24. Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, Chakravorty S, Jones M, Alland D. Evaluation of the analytical performance of the Xpert MTB/RIF assay. Journal of clinical microbiology. 2010 Jul 1;48(7):2495-501.

25. American Thoracic Society. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161:S221-47.

26. David H, Lévy-Frébault V, Thorel MF. Méthodes de LaboratoirepourMycobactériologie Clinique. Institute Pasteur, Paris. 1989:85.

27. Ioannidis P, Papaventsis D, Karabela S, Nikolaou S, Panagi M, Raftopoulou E, Konstantinidou E, Marinou I, Kanavaki S. Cepheid GeneXpert MTB/RIF Assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with high clinical suspicion of TB and smear negative microscopy. Journal of clinical microbiology. 2011 Jun 15:JCM-00718.

28. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane database of systematic reviews. 2013(1).

29. Lawson L, Habib AG, Okobi MI, Idiong D, Olajide I, Emenyonu N, Onuoha N, Cuevas LE, Ogiri SO. Pilot study on multidrug resistant tuberculosis in Nigeria. Annals of African medicine. 2010;9(3).

30. Idigbe O, Sofola T, Akinosho R, Onwujekwe D, Odiah F, Okoye R. Initial drug resistance tuberculosis amongst HIV seropositive and seronegative prison inmates in Lagos, Nigeria. InInt Conf AIDS 1998 (Vol. 12, p. 137).

31. Guenaoui K, Harir N, Ouardi A, Zeggai S, Sellam F, Bekri F, Touil SC. Use of GeneXpert Mycobacterium tuberculosis/rifampicin for rapid detection of rifampicin resistant Mycobacterium tuberculosis strains of clinically suspected multi-drug resistance tuberculosis cases. Annals of translational medicine. 2016 May;4(9). Shah A, Agarwal S, Shah K. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India. The International Journal of Tuberculosis and Lung Disease. 2002 Dec 1;6(12):1098-101.

32. Chowgule RV, Deodhar L. Pattern of secondary acquired drug resistance to antituberculosis drug in Mumbai, India--1991-1995. The Indian journal of chest diseases & allied sciences. 1998;40(1):23-31.